Deals this week: Fresenius Medical Care, Senseonics, Sonion

15 June 2018 (Last Updated July 27th, 2018 07:37)

Fresenius Medical Care has signed a global partnership agreement to commercialise Humacyte's investigational human acellular vessel Humacyl.

Fresenius Medical Care has signed a global partnership agreement to commercialise Humacyte’s investigational human acellular vessel Humacyl.

Fresenius Medical Care will be responsible for its marketing and distribution following the approval by health authorities.

The transaction will be closed in July, subject to customary closing conditions and other regulatory approvals.

Based in Germany, Fresenius Medical Care is a supplier of renal dialysis products, while Humacyte is a US-based medical research and development company focused on novel technologies.

The partnership will enable Humacyte to advance the development of Humacyl and continue the development of its future pipeline products.

Senseonics has entered an agreement to integrate its Eversense Continuous Glucose Monitoring (CGM) system with Beta Bionics’s bionic pancreas system.

“The partnership will enable Humacyte to advance the development of Humacyl and continue the development of its future pipeline products.”

Based in the US, Senseonics focuses on the development of glucose monitoring products, while Beta Bionics, also based in the US, is a developer of bionic pancreas system iLet.

Sonion and Valencell have partnered to expand the use of biometric sensors for hearing instruments in the health, medical and consumer device markets.

Valencell will provide biometric sensor modules for hearables and wearables, which Sonion will optimise for size and cost for in-ear and on-ear applications, as part of the collaboration.

Valencell has also secured an undisclosed investment from Sonion through the strategic partnership.

Based in the US, Valencell is a manufacturer of wearable biometric sensor systems, while Sonion, also based in the US, is a manufacturer of micro-acoustic components for hearing aids.

The partnership will enable Valencell to strengthen its position in the hearables and hearing health markets.